Rapport Therapeutics Management
Management criteria checks 1/4
Rapport Therapeutics' CEO is Abe Ceesay, appointed in Feb 2023, has a tenure of 1.83 years. total yearly compensation is $2.42M, comprised of 16.6% salary and 83.4% bonuses, including company stock and options. directly owns 2.16% of the company’s shares, worth $15.03M. The average tenure of the management team and the board of directors is 1.5 years and 1.3 years respectively.
Key information
Abe Ceesay
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 16.6% |
| CEO tenure | 1.8yrs |
| CEO ownership | 2.2% |
| Management average tenure | 1.5yrs |
| Board average tenure | 1.3yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$72m |
| Jun 30 2024 | n/a | n/a | -US$63m |
| Mar 31 2024 | n/a | n/a | -US$51m |
| Dec 31 2023 | US$2m | US$400k | -US$35m |
Compensation vs Market: Abe's total compensation ($USD2.42M) is about average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Insufficient data to compare Abe's compensation with company performance.
CEO
Abe Ceesay (46 yo)
1.8yrs
Tenure
US$2,415,840
Compensation
Mr. Abraham N. Ceesay, also known as Abe, MBA, serves as the Chief Executive Officer and President at Rapport Therapeutics, Inc. since February 2023 and serves as its Treasurer and serves as its Director s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Independent Chairman | 2yrs | US$568.99k | 1.31% $ 9.1m | |
| CEO, President | 1.8yrs | US$2.42m | 2.16% $ 15.0m | |
| Chief Financial Officer | 1.1yrs | US$2.48m | no data | |
| Chief Operating Officer | 1.3yrs | US$1.78m | 0.43% $ 3.0m | |
| Founder & Chief Scientific Officer | 1.9yrs | no data | 1.31% $ 9.1m | |
| Chief Information Officer & Head of Operations | no data | no data | no data | |
| Head of Communications & Investor Relations | less than a year | no data | no data | |
| Chief People Officer | less than a year | no data | no data | |
| Chief Medical Officer | 1.9yrs | no data | 0.54% $ 3.8m | |
| Chief Development Officer | 1.9yrs | no data | 0.80% $ 5.5m | |
| Senior Vice President of Medical Affairs | no data | no data | no data | |
| Senior Vice President of CMC & Product Development | no data | no data | no data |
1.5yrs
Average Tenure
57yo
Average Age
Experienced Management: RAPP's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Independent Chairman | 2yrs | US$568.99k | 1.31% $ 9.1m | |
| CEO, President | 1.8yrs | US$2.42m | 2.16% $ 15.0m | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 1.3yrs | no data | 0.24% $ 1.7m | |
| Director | less than a year | no data | no data | |
| Co-Chair of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 2.8yrs | US$400.23k | no data | |
| Co-Chair of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board & Director | 1.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
1.3yrs
Average Tenure
59.5yo
Average Age
Experienced Board: RAPP's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 18:03 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rapport Therapeutics, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Salveen Richter | Goldman Sachs |
| Lin Tsai | Jefferies LLC |
| Justin Walsh | JonesTrading Institutional Services, LLC |